European Biotechnology--A Question of Control
This article was originally published in Start Up
Executive Summary
European biotech companies have only partnered a third of the development drugs in their collective pipelines. With product-hungry Big Pharma prepared to pay ever-higher prices to in-license, much of the European biotech industry is in a strong position.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?